1. Home
  2. News
  3. Arteris, Inc.
  4. Arteris Announces Financial Results for the Fourth Quarter and Full Year 2025 and Estimated First Quarter and Full Ye...
Arteris, Inc. news

Investor announcements, newest first.

Close
Company news
Arteris, Inc.
Feb 12, 2026 at 9:05 PM UTC
Original
ELI5

Arteris Announces Financial Results for the Fourth Quarter and Full Year 2025 and Estimated First Quarter and Full Year 2026 Guidance

CAMPBELL, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced financial results for the fourth quarter and year ended December 31, 2025 and provided estimated first quarter and full year 2026 guidance.

“In the fourth quarter of 2025, we again delivered strong financial results, including a new record of Annual Contract Value plus royalties reaching $83.6 million, representing 28% year-over-year growth. During the quarter, our customers surpassed the milestone of more than four billion systems shipped with SoCs connected by Arteris System IP, and we enjoyed royalty growth of 50% year-over-year,” said K. Charles Janac, President and CEO of Arteris. “As cybersecurity threats intensify not just in software but the underlying hardware used across data centers, edge devices, and mission-critical systems, our recent acquisition of Cycuity strengthens Arteris’ ability to help customers secure data movement in silicon through proven technology and deep domain expertise. Combined with the acceleration of AI use in semiconductors and the ever increasing SoC complexities created by the proliferation of chiplet-based, multi-die architectures, Arteris is well positioned to deliver on these transformative opportunities,” concluded Janac.

Fourth Quarter 2025 Financial Highlights:

  • Revenue of $20.1 million, up 30% year-over-year

  • Annual Contract Value (ACV) plus royalties of $83.6 million, up 28% year-over-year, growing to the highest level we have ever reported

  • Remaining performance obligation (RPO) of $116.8 million, up 32% year-over-year, growing to the highest level we have ever reported. We expect approximately half of our RPO will be recognized as revenue in 2026. This projection excludes cancelable and non-cancelable Flexible Spending Accounts.

  • Operating loss of $8.5 million, compared to an operating loss of $7.1 million in the fourth quarter of 2024

  • Non-GAAP operating loss of $2.2 million, compared to a Non-GAAP operating loss of $2.8 million in the fourth quarter of 2024

  • Net loss of $8.5 million or $0.19 per share

  • Non-GAAP net loss of $2.3 million or $0.05 per share

  • Non-GAAP free cash flow of positive $3.0 million or 15% of revenue

Full year 2025 Financial Highlights:

  • Revenue of $70.6 million, up 22% year-over-year

  • Variable royalties of $6.6 million, up 50% year-over-year

  • Operating loss of $33.1 million, compared to an operating loss of $31.6 million for the year ended 2024

  • Non-GAAP operating loss of $12.5 million, compared to a Non-GAAP operating loss of $14.8 million for the year ended 2024

  • Net loss of $34.7 million or $0.82 per share

  • Non-GAAP net loss of $14.1 million or $0.33 per share

  • Non-GAAP free cash flow of positive $5.3 million or 8% of revenue

Recent Business Highlights:

  • In January 2026, we closed the acquisition of Cycuity, a leading provider of semiconductor security verification software. This acquisition strengthens Arteris’ product portfolio, enabling customers to improve security in IP blocks, chiplets, SoCs and firmware;

  • Our customers have shipped over four billion SoC chips and chiplets incorporating Arteris network-on-chip technology as the underlying interconnect since Arteris' inception;

  • FlexGen smart NoC IP has seen strong customer adoption, ending the year with over 30 production device deployments by 10 different customers;

  • In February 2026, we announced NXP’s expanded use of Arteris products across its AI enabled silicon solutions for intelligent vehicles, advanced industrial systems, and consumer electronics. This deployment includes Ncore cache coherent interconnect, FlexNoC non-coherent interconnect, CodaCache last-level cache IP, and Magillem software for SoC integration;

  • We announced that Black Sesame is licensing both Ncore and FlexNoC IP for its next-generation of advanced automotive semiconductors;

  • Blaize deployed FlexNoC IP for its Blaize AI platform, delivering a programmable, energy-efficient solution spanning edge and cloud-based AI; and

  • Arteris became a founding member of the CHASSIS program, an initiative led by Bosch and includes automotive OEMs such as BMW, Renault, and Stellantis, with the goal of creating an open automotive chiplet platform.

Non-GAAP gross profit, Non-GAAP gross margin, Non-GAAP operating loss, Non-GAAP net loss, Non-GAAP net loss per share, and free cash flow are Non-GAAP financial measures. Additional information on Arteris’ historic reported results, including a reconciliation of these Non-GAAP financial measures to their most comparable GAAP measures, is included in the financial tables below.

Estimated First Quarter and Full Year 2026 Guidance:

 

Q1 2026

FY 2026

 

(in millions)

ACV + royalties

$85.0 - $89.0

$100.0 - $104.0

Revenue

$20.5 - $21.5

$89.0 - $93.0

Non-GAAP operating loss

$2.5 - $3.5

$5.0 - $9.0

Free cash flow

($1.5) - $1.5

$5.0 - $9.0

 

 

 

The guidance provided above are forward-looking statements and reflects Arteris' expectations as of today's date. Actual results may differ materially. Refer to the section titled "Forward-Looking Statements" below for information on the factors, among others, that could cause our actual results to differ materially from these forward-looking statements.

A reconciliation of Non-GAAP guidance measures reported above to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Arteris' results computed in accordance with GAAP.

Definitions of the other business metrics used in this press release including ACV, confirmed design starts and RPO are included below under the heading “Other Business Metrics.”

Conference Call

Arteris will host a conference call today on February 12, 2026 to review its fourth quarter and full year 2025 financial results and to discuss its financial outlook.

 

Time:

4:30PM ET

 

 

United States/Canada Toll Free:

1-800-717-1738

 

 

International Toll:

1-646-307-1865

 

 

 

 

 

A live webcast will also be available in the Investor Relations section of Arteris’ website at: https://ir.arteris.com/events-and-presentations

A replay of the webcast will be available in the Investor Relations section of Arteris' website approximately two hours after the conclusion of the call and remain available for approximately 30 calendar days.

About Arteris

Arteris is a leading provider of semiconductor technology that accelerates the creation of high-performance, power-efficient silicon with built-in safety, reliability, and security. Innovative Arteris products are designed to optimize data movement and help ease complexity in the modern AI era with network-on-chip (NoC) interconnect intellectual property (IP), system-on-chip (SoC) software for integration automation and hardware security assurance. All are used by the world’s top technology companies to improve overall performance and engineering productivity, reduce risk, lower costs, and bring cutting-edge designs to market faster. Learn more at arteris.com.

© 2004-2026 Arteris, Inc. All rights reserved worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other Arteris marks found at https://www.arteris.com/trademarks are trademarks or registered trademarks of Arteris, Inc. or its subsidiaries. All other trademarks are the property of their respective owners.

Investor Contacts:
Arteris
Nick Hawkins
Chief Financial Officer
[email protected]

Sapphire Investor Relations, LLC
Erica Mannion and Michael Funari
+1 617 542 6180
[email protected]

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including but not limited to, statements regarding market trends and whether we are well positioned to capture these opportunities, our long-term growth opportunity and future financial and operating performance, including our GAAP and Non-GAAP estimated first quarter and full year 2026 guidance. The words such as "may," "will," "could," "expect," "approximately," "believe," "estimate," "future," "guidance," "outlook," and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements contained herein are based on our historical performance and our current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent our expectations as of the date of this press release. Subsequent events may cause these expectations to change, and we disclaim any obligation to update the forward-looking statements in the future, except as required by law. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from our current expectations. Important factors that could cause actual results to differ materially from those anticipated in our forward-looking statements include, but are not limited to, the significant competition we face from larger companies and third-party providers; our history of net losses; the amount of our future revenue recognition as it relates to our RPO as of December 31, 2025; whether semiconductor companies in the aerospace and defense market, automotive market, communications market, consumer electronics market, enterprise computing market, and industrial market incorporate our solutions into their end products and the growth and economic stability of these end markets; our ability to attract new customers and the extent to which our customers renew their subscriptions for our solutions; the ability of our customers’ end products achieving market acceptance or growth; our ability to sustain or grow our licensing revenue; our ability, and the cost, to successfully execute on research and development efforts; the occurrence of product errors or defects in our solutions; if we fail to offer high-quality support; the occurrence of macro-economic conditions that adversely impact us, our customers and their end product markets including, but not limited to, the imposition of tariffs in markets where we operate; the effects of geopolitical conflicts, such as the military conflict between Russia and Ukraine as well as the ongoing conflict in the Middle East; the range of regulatory, operational, financial and political risks we are exposed to as a result of our dependence on international customers and operations; our ability to protect our proprietary technology and inventions through patents and other IP rights; whether we are subject to any liabilities or fines as a result of government regulation, including import, export and economic sanctions laws and regulations; the occurrence of a disruption in our networks or a security breach; risks associated with doing business in China, including as a result of changes to trade relations between the United States and China; and the other factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 to be filed with the Securities and Exchange Commission (SEC) on or about February 12, 2026. All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances. Our results for the quarter and year ended December 31, 2025 are not necessarily indicative of our operating results for any future periods.


 

Arteris, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Revenue

 

 

 

 

 

 

 

Licensing, support and maintenance

$

17,540

 

 

$

14,016

 

 

$

63,859

 

 

$

52,815

 

Variable royalties and other

 

2,597

 

 

 

1,473

 

 

 

6,720

 

 

 

4,909

 

Total revenue

 

20,137

 

 

 

15,489

 

 

 

70,579

 

 

 

57,724

 

Cost of revenue

 

1,861

 

 

 

1,575

 

 

 

6,895

 

 

 

5,962

 

Gross profit

 

18,276

 

 

 

13,914

 

 

 

63,684

 

 

 

51,762

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

13,227

 

 

 

11,532

 

 

 

49,908

 

 

 

45,007

 

Sales and marketing

 

7,068

 

 

 

5,365

 

 

 

26,782

 

 

 

20,796

 

General and administrative

 

6,448

 

 

 

4,119

 

 

 

20,131

 

 

 

17,555

 

Total operating expenses

 

26,743

 

 

 

21,016

 

 

 

96,821

 

 

 

83,358

 

Loss from operations

 

(8,467

)

 

 

(7,102

)

 

 

(33,137

)

 

 

(31,596

)

Interest expense

 

(54

)

 

 

(45

)

 

 

(193

)

 

 

(244

)

Other income (expense), net

 

732

 

 

 

824

 

 

 

2,872

 

 

 

3,400

 

Loss before income taxes and loss from equity method investment

 

(7,789

)

 

 

(6,323

)

 

 

(30,458

)

 

 

(28,440

)

Loss from equity method investment, net of tax

 

734

 

 

 

634

 

 

 

2,813

 

 

 

2,698

 

Loss before income taxes

 

(8,523

)

 

 

(6,957

)

 

 

(33,271

)

 

 

(31,138

)

Provision for (benefit from) income taxes

 

(19

)

 

 

1,247

 

 

 

1,475

 

 

 

2,500

 

Net loss

$

(8,504

)

 

$

(8,204

)

 

$

(34,746

)

 

$

(33,638

)

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

$

(0.19

)

 

$

(0.20

)

 

$

(0.82

)

 

$

(0.86

)

Weighted-average shares used in computing per share amounts, basic and diluted

 

43,710,109

 

 

 

40,157,199

 

 

 

42,290,619

 

 

 

38,914,197

 


 

Arteris, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)

 

 

As of December 31,

 

 

2025

 

 

 

2024

 

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

33,901

 

 

$

13,684

 

Short-term investments

 

20,698

 

 

 

30,157

 

Accounts receivable, net of allowance of $73 and $131 as of December 31, 2025, and 2024, respectively

 

19,183

 

 

 

20,608

 

Prepaid expenses and other current assets

 

8,608

 

 

 

4,634

 

Total current assets

 

82,390

 

 

 

69,083

 

Property and equipment, net

 

3,872

 

 

 

4,019

 

Long-term investments

 

4,946

 

 

 

8,504

 

Equity method investment

 

2,989

 

 

 

5,802

 

Operating lease right-of-use assets

 

3,919

 

 

 

3,838

 

Intangibles, net

 

2,168

 

 

 

3,024

 

Goodwill

 

4,178

 

 

 

4,178

 

Other assets

 

10,569

 

 

 

7,687

 

TOTAL ASSETS

$

115,031

 

 

$

106,135

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

340

 

 

$

539

 

Accrued expenses and other current liabilities

 

19,094

 

 

 

15,899

 

Operating lease liabilities, current

 

1,233

 

 

 

917

 

Deferred revenue, current

 

51,367

 

 

 

40,445

 

Vendor financing arrangements, current

 

1,166

 

 

 

1,482

 

Total current liabilities

 

73,200

 

 

 

59,282

 

Deferred revenue, noncurrent

 

43,974

 

 

 

35,177

 

Operating lease liabilities, noncurrent

 

3,116

 

 

 

2,998

 

Vendor financing arrangements, noncurrent

 

452

 

 

 

594

 

Deferred income, noncurrent

 

6,452

 

 

 

7,631

 

Other liabilities

 

2,469

 

 

 

1,641

 

Total liabilities

 

129,663

 

 

 

107,323

 

Stockholders’ deficit:

 

 

 

Preferred stock, par value of $0.001—10,000,000 shares authorized and no shares issued and outstanding as of both December 31, 2025, and 2024

 

—

 

 

 

—

 

Common stock, par value of $0.001—300,000,000 shares authorized at December 31, 2025, and 2024; 44,268,816 and 40,724,936 shares issued and outstanding at December 31, 2025, and 2024, respectively

 

44

 

 

 

40

 

Additional paid-in capital

 

156,776

 

 

 

135,522

 

Accumulated other comprehensive income

 

179

 

 

 

135

 

Accumulated deficit

 

(171,631

)

 

 

(136,885

)

Total stockholders’ deficit

 

(14,632

)

 

 

(1,188

)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

$

115,031

 

 

$

106,135

 


 

Arteris, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)

 

 

Twelve Months Ended
December 31,

 

 

2025

 

 

 

2024

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

Net loss

$

(34,746

)

 

$

(33,638

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

Depreciation and amortization

 

3,376

 

 

 

3,362

 

Stock-based compensation

 

18,376

 

 

 

15,938

 

Pension plan expenses

 

201

 

 

 

163

 

Amortization of deferred income

 

(1,179

)

 

 

(1,182

)

Loss from equity method investment

 

2,813

 

 

 

2,698

 

Net accretion of discounts on available-for-sale securities

 

(368

)

 

 

(695

)

Other, net

 

401

 

 

 

(9

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable, net

 

1,425

 

 

 

(8,605

)

Prepaid expenses and other assets

 

(6,347

)

 

 

(1,068

)

Accounts payable

 

(191

)

 

 

324

 

Accrued expenses and other liabilities

 

3,253

 

 

 

3,079

 

Deferred revenue

 

19,719

 

 

 

18,913

 

 Net cash provided by (used in) operating activities

 

6,733

 

 

 

(720

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

Purchases of property and equipment

 

(1,388

)

 

 

(324

)

Purchases of available-for-sale securities and other

 

(29,528

)

 

 

(37,175

)

Proceeds from maturities and sales of available-for-sale securities and other

 

42,944

 

 

 

38,469

 

 Net cash provided by investing activities

 

12,028

 

 

 

970

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

Principal payments under vendor financing arrangements

 

(1,503

)

 

 

(1,749

)

Proceeds from exercise of stock options

 

1,866

 

 

 

890

 

Proceeds from employee stock purchase plan

 

982

 

 

 

538

 

Other financing activities

 

72

 

 

 

59

 

 Net cash provided by (used in) financing activities

 

1,417

 

 

 

(262

)

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

20,178

 

 

 

(12

)

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period

 

14,072

 

 

 

14,084

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period

$

34,250

 

 

$

14,072

 


Non-GAAP Financial Measures

To supplement our financial results, which are prepared and presented in accordance with GAAP, we use certain non-GAAP financial measures, as described below, to understand and evaluate our core performance. These non-GAAP measures, which may be different than similarly-titled measures used by other companies, are presented to enhance investors’ overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We define "Non-GAAP gross profit" and "Non-GAAP gross margin" as GAAP gross profit and GAAP gross margin, respectively, adjusted for stock-based compensation expense included in cost of revenue and amortization of acquired intangible assets included in cost of revenue. We define “Non-GAAP loss from operations” as our GAAP loss from operations adjusted to exclude stock-based compensation expense, amortization of acquired intangible assets and acquisition-related costs. We define “Non-GAAP net loss” as our net loss adjusted to exclude stock-based compensation, amortization of acquired intangible assets and acquisition-related costs.

We define “Non-GAAP net loss per share attributable to common stockholders, basic and diluted”, as our Non-GAAP net loss divided by our GAAP weighted-average number of shares outstanding for the period on a basic or diluted basis, respectively. Management uses this non-GAAP measure to evaluate the performance of our business on a comparable basis from period to period.

The above items are excluded from our Non-GAAP gross profit, Non-GAAP loss from operations and Non-GAAP net loss because these items are non-cash in nature, or are not indicative of our core operating performance, and render comparisons with prior periods and competitors less meaningful. We believe Non-GAAP gross profit, Non-GAAP loss from operations and Non-GAAP net loss provide useful supplemental information to investors and others in understanding and evaluating our results of operations, as well as provide a useful measure for period-to-period comparisons of our business performance.

We define free cash flow as net cash provided by operating activities less cash used for purchases of property and equipment. We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors, even if negative, about the amount of cash provided by (used in) our operations other than that used for investments in property and equipment.

Other Business Metrics

Annual Contract Value (ACV) – we define Annual Contract Value for an individual customer agreement as the total fixed fees under the agreement divided by the number of years in the agreement term. Our total ACV is the aggregate ACVs for all our customers as measured at a given point in time. Total fixed fees includes licensing, support and maintenance and other fixed fees under IP licensing or software licensing agreements but excludes variable revenue derived from licensing agreements with customers, particularly royalties. We define ACV plus royalties as ACV plus the trailing-twelve-months variable royalties and other revenue.

Confirmed Design Starts – we define Confirmed Design Starts as when customers confirm their commencement of new semiconductor designs using our interconnect IP and notify us. Confirmed Design Starts is a metric management uses to assess the activity level of our customers in terms of the number of new semiconductor designs that are started using our interconnect IP in a given period. We believe that the number of Confirmed Design Starts is an important indicator of the growth of our business and future royalty revenue trends.

Remaining Performance Obligations (RPO) – we define Remaining Performance Obligations as the amount of contracted future revenue that has not yet been recognized, including deferred revenue, billed and unbilled cancelable and non-cancelable contracted amounts.

Arteris, Inc.
Reconciliation of GAAP Measures to Non-GAAP Measures
(In thousands, except share and per share data)
(Unaudited)

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Gross profit

$

18,276

 

 

$

13,914

 

 

$

63,684

 

 

$

51,762

 

Add:

 

 

 

 

 

 

 

Stock-based compensation expense included in cost of revenue

 

212

 

 

 

187

 

 

 

877

 

 

 

783

 

Amortization of acquired intangible assets(1)

 

50

 

 

 

49

 

 

 

200

 

 

 

199

 

Non-GAAP gross profit

$

18,538

 

 

$

14,150

 

 

$

64,761

 

 

$

52,744

 

Gross margin

 

91

%

 

 

90

%

 

 

90

%

 

 

90

%

Non-GAAP gross margin

 

92

%

 

 

91

%

 

 

92

%

 

 

91

%

 

 

 

 

 

 

 

 

Research and development

$

13,227

 

 

$

11,532

 

 

$

49,908

 

 

$

45,007

 

Stock-based compensation expense

 

(1,996

)

 

 

(1,959

)

 

 

(7,990

)

 

 

(7,509

)

Amortization of acquired intangible assets(1)

 

(82

)

 

 

(109

)

 

 

(412

)

 

 

(389

)

Non-GAAP research and development

$

11,149

 

 

$

9,464

 

 

$

41,506

 

 

$

37,109

 

 

 

 

 

 

 

 

 

Sales and marketing

$

7,068

 

 

$

5,365

 

 

$

26,782

 

 

$

20,796

 

Stock-based compensation expense

 

(1,140

)

 

 

(849

)

 

 

(4,492

)

 

 

(3,079

)

Amortization of acquired intangible assets(1)

 

(58

)

 

 

(58

)

 

 

(229

)

 

 

(229

)

Non-GAAP sales and marketing

$

5,870

 

 

$

4,458

 

 

$

22,061

 

 

$

17,488

 

 

 

 

 

 

 

 

 

General and administrative

$

6,448

 

 

$

4,119

 

 

$

20,131

 

 

$

17,555

 

Stock-based compensation expense

 

(1,263

)

 

 

(1,136

)

 

 

(5,017

)

 

 

(4,567

)

Acquisition-related costs

 

(1,448

)

 

 

—

 

 

 

(1,448

)

 

 

—

 

Non-GAAP general and administrative

$

3,737

 

 

$

2,983

 

 

$

13,666

 

 

$

12,988

 

 

 

 

 

 

 

 

 

Total operating expenses

$

26,743

 

 

$

21,016

 

 

$

96,821

 

 

$

83,358

 

Stock-based compensation expense

 

(4,399

)

 

 

(3,944

)

 

 

(17,499

)

 

 

(15,155

)

Amortization of acquired intangible assets(1)

 

(140

)

 

 

(167

)

 

 

(641

)

 

 

(618

)

Acquisition-related costs

 

(1,448

)

 

 

—

 

 

 

(1,448

)

 

 

—

 

Total Non-GAAP operating expenses

$

20,756

 

 

$

16,905

 

 

$

77,233

 

 

$

67,585

 

 

 

 

 

 

 

 

 

Loss from operations

$

(8,467

)

 

$

(7,102

)

 

$

(33,137

)

 

$

(31,596

)

Stock-based compensation expense

 

4,611

 

 

 

4,131

 

 

 

18,376

 

 

 

15,938

 

Amortization of acquired intangible assets(1)

 

190

 

 

 

216

 

 

 

841

 

 

 

817

 

Acquisition-related costs(2)

 

1,448

 

 

 

—

 

 

 

1,448

 

 

 

—

 

Non-GAAP loss from operations

$

(2,218

)

 

$

(2,755

)

 

$

(12,472

)

 

$

(14,841

)

 

 

 

 

 

 

 

 

Net loss

$

(8,504

)

 

$

(8,204

)

 

$

(34,746

)

 

$

(33,638

)

Stock-based compensation expense

 

4,611

 

 

 

4,131

 

 

 

18,376

 

 

 

15,938

 

Amortization of acquired intangible assets(1)

 

190

 

 

 

216

 

 

 

841

 

 

 

817

 

Acquisition-related costs(2)

 

1,448

 

 

 

—

 

 

 

1,448

 

 

 

—

 

Non-GAAP net loss(3)

$

(2,255

)

 

$

(3,857

)

 

$

(14,081

)

 

$

(16,883

)

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

$

(0.19

)

 

$

(0.20

)

 

$

(0.82

)

 

$

(0.86

)

Per share impacts of adjustments to net loss(4)

$

0.14

 

 

$

0.10

 

 

$

0.49

 

 

$

0.43

 

Non-GAAP net loss per share attributable to common stockholders, basic and diluted

$

(0.05

)

 

$

(0.10

)

 

$

(0.33

)

 

$

(0.43

)

 

 

 

 

 

 

 

 

Weighted-average shares used in computing per share amounts, basic and diluted

 

43,710,109

 

 

 

40,157,199

 

 

 

42,290,619

 

 

 

38,914,197

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Represents the amortization expenses of our intangible assets attributable to our acquisitions.
(2) Includes advisory, legal, accounting, valuation, and other professional or consulting fees associated with the Cycuity acquisition and recorded in general and administrative.
(3) Our GAAP tax provision is primarily related to foreign withholding taxes and income tax in profitable foreign jurisdictions. We maintain a full valuation allowance against our deferred tax assets in the US. Accordingly, there is no significant tax impact associated with these Non-GAAP adjustments.
(4) Reflects the aggregate adjustments made to reconcile Non-GAAP net loss to our net loss as noted in the above table, divided by the GAAP diluted weighted average number of shares of the relevant period.


Free Cash Flow

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Net cash used in (provided by) operating activities

 

$

3,170

 

 

$

(2,631

)

 

$

6,733

 

 

$

(720

)

Less:

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(134

)

 

 

(50

)

 

 

(1,388

)

 

 

(324

)

Free cash flow

 

$

3,036

 

 

$

(2,681

)

 

$

5,345

 

 

$

(1,044

)

Net cash provided by (used in) investing activities

 

$

13,075

 

 

$

(1,928

)

 

$

12,028

 

 

$

970

 

Net cash provided by (used in) financing activities

 

$

142

 

 

$

414

 

 

$

1,417

 

 

$

(262

)